{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:19:39Z","timestamp":1790075979605,"version":"4.0.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3410,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Spontaneous resolution of acute hepatitis C virus infection cannot be predicted, and chronic evolution of the disease occurs in a majority of cases. To assess the efficacy and safety of peginterferon alpha-2b administered for 8, 12, or 24 weeks in patients with acute hepatitis C virus infection a total of 161 patients were identified with acute hepatitis C virus infection. Of these, 30 patients refused treatment but were retained in the study as a nonrandomized comparison group. Of the 131 patients who consented to treatment, 29 patients spontaneously resolved, leaving 102 patients randomly assigned to peginterferon alpha-2b (1.5 \u03bcg\/kg) for 8 weeks (group A; n = 34), 12 weeks (group B; n = 34), and 24 weeks (group C; n = 34). The primary end point was sustained virologic response. An intent-to-treat analysis was used for efficacy and safety end points. Sustained virologic response was achieved in 23\/34 (67.6%), 28\/34 (82.4%), and 31\/34 (91.2%) of patients in groups A, B, and C, respectively; all had undetectable hepatitis C virus RNA 48 weeks after the end of therapy. Treatment for 8 or 12 weeks was effective in genotypes 2, 3, and 4, whereas genotype 1 required 24 weeks of therapy. The 8- and 12-week regimens were associated with fewer adverse events compared with the 24-week regimen.<\/jats:bold>\n                                 <jats:bold>\n                                    In conclusion\n                                 <\/jats:bold>\n                                 <jats:bold>, peginterferon alpha-2b effectively induces high sustained virologic response rates in patients with acute hepatitis C virus infection, thus preventing development of chronic hepatitis C. Duration of treatment should be further optimized based on genotype and rapid virologic response at week 4. (Hepatology 2006;43:923\u2013931.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.21197","type":"journal-article","created":{"date-parts":[[2006,4,20]],"date-time":"2006-04-20T18:51:48Z","timestamp":1145559108000},"page":"923-931","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":106,"title":["Duration of peginterferon therapy in acute hepatitis C: A randomized trial"],"prefix":"10.1097","volume":"43","author":[{"given":"Sanaa M.","family":"Kamal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khairy N.","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Fehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza Abdel","family":"Moneim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalifa E.","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila A.","family":"El Gohary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr H.","family":"Ramy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Madwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Rasenack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nezam H.","family":"Afdhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl","key":"R1-9-20241201","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of hepatitis C.","volume":"36","author":"Hoofnagle","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R2-9-20241201","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-132-4-200002150-00008","article-title":"Pathogenesis, natural history, treatment, and prevention of hepatitis C.","volume":"132","author":"Liang","year":"2000","journal-title":"Ann Intern Med"},{"key":"R3-9-20241201","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1089-3261(05)70321-4","article-title":"The epidemiology of acute and chronic hepatitis C.","volume":"1","author":"Alter","year":"1997","journal-title":"Clin Liver Dis"},{"key":"R4-9-20241201","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/jhep.2001.22112","article-title":"Acute hepatitis C.","volume":"33","author":"Orland","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R5-9-20241201","doi-asserted-by":"crossref","first-page":"12252","DOI":"10.1128\/JVI.78.22.12252-12258.2004","article-title":"Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients.","volume":"78","author":"Kamal","year":"2004","journal-title":"J Virol"},{"key":"R6-9-20241201","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jmv.20265","article-title":"Molecular investigation of interspousal transmission of hepatitis C virus in two Japanese patients who acquired acute hepatitis C after 40 or 42 years of marriage.","volume":"75","author":"Nakayama","year":"2005","journal-title":"J Med Virol"},{"issue":"Suppl 1","key":"R7-9-20241201","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C.","volume":"36","author":"Seeff","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R8-9-20241201","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0140-6736(91)91774-O","article-title":"Resolution of acute hepatitis C after therapy with natural beta interferon.","volume":"338","author":"Omata","year":"1991","journal-title":"Lancet"},{"key":"R9-9-20241201","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0168-8278(94)80246-7","article-title":"A randomized controlled trial of recombinant interferon alpha2b in the treatment of Chinese patients with acute posttransfusion hepatitis C.","volume":"21","author":"Hwang","year":"1994","journal-title":"J Hepatol"},{"issue":"Suppl","key":"R10-9-20241201","doi-asserted-by":"crossref","first-page":"81S","DOI":"10.1007\/BF02087880","article-title":"Highdose interferonalfa2b treatment prevents chronicity in acute hepatitis C: a pilot study.","volume":"41","author":"Vogel","year":"1996","journal-title":"Dig Dis Sci"},{"key":"R11-9-20241201","first-page":"181","article-title":"Natural beta interferon in acute typeC hepatitis patients: a randomized controlled trial.","volume":"30","author":"Calleri","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"R12-9-20241201","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa2b.","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"R13-9-20241201","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C: high rate of both spontaneous and treatmentinduced viral clearance.","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"R14-9-20241201","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.1840190105","article-title":"A multicenter randomized controlled trial of recombinant interferonalpha 2b in patients with acute transfusionassociated hepatitis C.","volume":"19","author":"Lampertico","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R15-9-20241201","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.20196","article-title":"Shortterm interferonalfa therapy for acute hepatitis C.","volume":"39","author":"Nomura","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R16-9-20241201","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/hep.20266","article-title":"Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virusspecific T cell response kinetics.","volume":"39","author":"Kamal","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R17-9-20241201","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0016-5085(99)70353-7","article-title":"Recurrence of hepatitis C virus after loss of virus specific CD 4 Tcell response in acute hepatitis C.","volume":"117","author":"Gerlach","year":"1999","journal-title":"Gastroenterology"},{"key":"R18-9-20241201","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/gast.2001.27024","article-title":"Acute hepatitis C without and with schistosomiasis: correlation with hepatitis Cspecific CD4 () Tcell and cytokine response.","volume":"121","author":"Kamal","year":"2001","journal-title":"Gastroenterology"},{"key":"R19-9-20241201","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1053\/j.gastro.2006.01.034","article-title":"Peginterferon alfa2b therapy in acute hepatitis C: impact of onset of therapy on sustained virological response.","volume":"130","author":"Kamal","year":"2006","journal-title":"Gastroenterology"},{"issue":"Pt 1","key":"R20-9-20241201","first-page":"294","article-title":"Early treatment of acute hepatitis C with interferon alpha2b or interferon alpha2b plus ribavirin: study of sixteen patients.","volume":"3","author":"Rocca","year":"2003","journal-title":"Gastroenterol Clin Biol"},{"key":"R21-9-20241201","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2004.11.021","article-title":"Efficacy of a 24week course of PEGinterferon alpha2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.","volume":"42","author":"Santantonio","year":"2005","journal-title":"J Hepatol"},{"key":"R22-9-20241201","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.20291","article-title":"Longterm followup after successful interferon therapy of acute hepatitis C.","volume":"40","author":"Wiegand","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R23-9-20241201","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/hep.20467","article-title":"Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.","volume":"40","author":"Dalgard","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R24-9-20241201","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa042608","article-title":"Peginterferon alfa2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.","volume":"352","author":"Mangia","year":"2005","journal-title":"N Engl J Med"},{"key":"R25-9-20241201","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R26-9-20241201","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa2b plus ribavirin compared with interferon alfa2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R27-9-20241201","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/gut.2004.057182","article-title":"Peginterferonalpha 2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virologic response.","volume":"54","author":"Kamal","year":"2005","journal-title":"Gut"},{"key":"R28-9-20241201","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1478-3231.2004.0976.x","article-title":"Peginterferon alpha2b plus ribavirin compared with interferon alpha2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.","volume":"24","author":"Alfaleh","year":"2004","journal-title":"Liver Int"},{"key":"R29-9-20241201","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/jhep.2003.50364","article-title":"Early virologic response to treatment with peginterferon alfa2b plus ribavirin in patients with chronic hepatitis C.","volume":"38","author":"Davis","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R30-9-20241201","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jac\/dkh015","article-title":"Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies.","volume":"53","author":"Ferenci","year":"2004","journal-title":"J Antimicrob Chemother"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21197","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200605000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:02:04Z","timestamp":1733058124000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200605000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21197","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}